Register entry
- Registered sites
- 0
- Active NDC listings
- 20
- Live patents
- 0
- Shortage listings
- 5
- Countries
- 0
Alert
Drug shortage listings
5| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Nilutamide TabletOncology | Nilandron, Tablet, 150 mg (NDC 59212-111-14) | To Be Discontinued | - | 1 Dec 20251 Dec 2025 |
| Nilutamide TabletOncology | Nilandron, Tablet, 150 mg (NDC 66993-212-38) | To Be Discontinued | - | 1 Dec 20251 Dec 2025 |
| Phenoxybenzamine Hydrochloride CapsuleCardiovascular | Dibenzyline, Capsule, 10 mg (NDC 66993-066-02) | To Be Discontinued | - | 1 Dec 20251 Dec 2025 |
| Phenoxybenzamine Hydrochloride CapsuleCardiovascular | Dibenzyline, Capsule, 10 mg (NDC 59212-001-01) | To Be Discontinued | - | 1 Dec 20251 Dec 2025 |
| Phenoxybenzamine Hydrochloride CapsuleCardiovascular | Dibenzyline, Capsule, 10 mg (NDC 59212-001-02) | To Be Discontinued | - | 1 Dec 20251 Dec 2025 |
Catalogue
Drug listings by form and route
2020 active NDC listings: 20 human prescription drug. By marketing category: NDA 17, UNAPPROVED DRUG OTHER 3.
| Dosage form | NDCs |
|---|---|
| tablet | 5 |
| capsule | 4 |
| tablet, film coated | 3 |
| tablet, orally disintegrating | 3 |
| elixir | 2 |
| gel | 1 |
| insert, extended release | 1 |
| tablet, extended release | 1 |
| Route | NDCs |
|---|---|
| oral | 18 |
| topical | 1 |
| vaginal | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| advanz pharma (us) corp. | 20 |
Catalogue
Marketed products
20| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Donnatal | phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide | elixir, oral | 59212-422UNAPPROVED DRUG OTHER |
| Donnatal | phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide | elixir, oral | 59212-423UNAPPROVED DRUG OTHER |
| Donnatal | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE | tablet, oral | 59212-425UNAPPROVED DRUG OTHER |
| Dyrenium | Triamterene | capsule, oral | 59212-002NDA |
| Dyrenium | Triamterene | capsule, oral | 59212-003NDA |
| LANOXIN | digoxin | tablet, oral | 59212-240NDA |
| LANOXIN | digoxin | tablet, oral | 59212-242NDA |
| LANOXIN | digoxin | tablet, oral | 59212-249NDA |
| NuvaRing | etonogestrel and ethinyl estradiol | insert, extended release, vaginal | 59212-146NDA |
| Orapred ODT | prednisolone sodium phosphate | tablet, orally disintegrating, oral | 59212-700NDA |
| Orapred ODT | prednisolone sodium phosphate | tablet, orally disintegrating, oral | 59212-701NDA |
| Orapred ODT | prednisolone sodium phosphate | tablet, orally disintegrating, oral | 59212-702NDA |
| PANRETIN | alitretinoin | gel, topical | 59212-601NDA |
| PARNATE | tranylcypromine sulfate | tablet, film coated, oral | 59212-447NDA |
| Plaquenil | Hydroxychloroquine Sulfate | tablet, oral | 59212-562NDA |
| Salagen | Pilocarpine Hydrochloride | tablet, film coated, oral | 59212-705NDA |
| Salagen | Pilocarpine Hydrochloride | tablet, film coated, oral | 59212-775NDA |
| Uroxatral | Alfuzosin HCl | tablet, extended release, oral | 59212-200NDA |
| Zonegran | Zonisamide | capsule, oral | 59212-680NDA |
| Zonegran | Zonisamide | capsule, oral | 59212-681NDA |
Compare
Other companies listing digoxin
- Aphena Pharma Solutions - Tennessee, LLC0 sites · 795 NDC
- Covis Pharma US, Inc0 sites · 18 NDC
Enquiry
Common questions
- Is Advanz Pharma (US) Corp. FDA approved?
- Advanz Pharma (US) Corp. holds no registered establishment of its own; 20 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Advanz Pharma (US) Corp. make?
- 20 products are listed under Advanz Pharma (US) Corp. in the openFDA NDC Directory, most often as tablet; capsule; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.